Latest Content

Maurie Markman, MD, unpacks goals-of-care discussions in oncology.

Manish Patel, DO, discusses early evidence suggesting that AR inhibition may enhance the efficacy of immunotherapy in salivary gland cancer.

Zevor-cel produced durable responses in patients with relapsed/refractory multiple myeloma following at least 3 prior lines of therapy.

Lore Gruenbaum, PhD, discusses hot topics in mantle cell lymphoma like recently approved CAR T-cell therapies and where she sees the field moving next.

ASCO has published updates to the clinical practice guidelines for the use of systemic therapy across subsets of patients with thyroid cancer.

A BLA has been accepted in China seeking the approval of second-line trastuzumab pamirtecan for unresectable or metastatic HER2-positive breast cancer.

A large U.S. study showed that adults who have never been married face a significantly higher risk of developing cancer than those who have been married.

Sagar S. Patel, MD, discusses data from trials evaluating agents in the Orca platform and where they fit into hematologic malignancy treatment paradigms.

During an Onclive Peer Exchange, panelists examined the utility of ctDNA in bladder cancer and other GU malignancies.

Multi-cancer early detection testing has emerged as an exciting strategy to expand cancer screening.

IMPT generated similar physical QOL scores, local disease control, gastronomy tube dependence, and OS vs IMRT in oropharyngeal squamous cell carcinoma.

Ulrich Steidl, MD, PhD, has been named director of the Montefiore Einstein Comprehensive Cancer Center and vice president of cancer medicine at Montefiore Einstein.

Douglas Flora, MD, LSSBB, discusses how AI is helping oncologists keep up with an evolving field, reinvent care timelines, and connect with patients.